-
1
-
-
66949138112
-
Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in childrens hospitals in the United States.
-
Gerber JS, Coffin SE, Smathers SA, et al. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children’s hospitals in the United States. Clin Infect Dis. 2009;49:65-71
-
(2009)
Clin Infect Dis
, vol.49
, pp. 65-71
-
-
Gerber, J.S.1
Coffin, S.E.2
Smathers, S.A.3
-
2
-
-
79951821210
-
Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
-
Liu C, Bayer A, Cosgrove SE, et al.Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55
-
(2011)
Clin Infect Dis
, vol.52
-
-
Liu, C.1
Bayer, A.2
Cosgrove, S.E.3
-
3
-
-
77749255891
-
Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.
-
Welsh KJ, Abbott AN, Lewis EM, et al. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol. 2010;48:894-899
-
(2010)
J Clin Microbiol
, vol.48
, pp. 894-899
-
-
Welsh, K.J.1
Abbott, A.N.2
Lewis, E.M.3
-
4
-
-
62449183879
-
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
-
Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98
-
(2009)
Am J Health Syst Pharm
, vol.66
, pp. 82-98
-
-
Rybak, M.1
Lomaestro, B.2
Rotschafer, J.C.3
-
5
-
-
79953907324
-
Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
-
Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975-981
-
(2011)
Clin Infect Dis
, vol.52
, pp. 975-981
-
-
Kullar, R.1
Davis, S.L.2
Levine, D.P.3
-
6
-
-
79957606863
-
-
Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45:582-589
-
Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45:582-589
-
-
-
-
7
-
-
67649543995
-
Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
-
Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28:398-402
-
(2009)
Pediatr Infect Dis J
, vol.28
, pp. 398-402
-
-
Frymoyer, A.1
Hersh, A.L.2
Benet, L.Z.3
-
8
-
-
77951899851
-
Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
-
Frymoyer A, Hersh AL, Coralic Z, et al. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther. 2010;32:534-542
-
(2010)
Clin Ther
, vol.32
, pp. 534-542
-
-
Frymoyer, A.1
Hersh, A.L.2
Coralic, Z.3
-
9
-
-
33750344295
-
Population clinical pharmacology of children: modelling covariate effects.
-
Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819-829
-
(2006)
Eur J Pediatr
, vol.165
, pp. 819-829
-
-
Anderson, B.J.1
Allegaert, K.2
Holford, N.H.3
-
10
-
-
83455171788
-
Vancomycin: a review of population pharmacokinetic analyses.
-
Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012;51:1-13
-
(2012)
Clin Pharmacokinet
, vol.51
, pp. 1-13
-
-
Marsot, A.1
Boulamery, A.2
Bruguerolle, B.3
-
11
-
-
0029145482
-
Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.
-
Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J. 1995;14:667-673
-
(1995)
Pediatr Infect Dis J
, vol.14
, pp. 667-673
-
-
Chang, D.1
-
12
-
-
0028125336
-
A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.
-
Chang D, Liem L, Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J. 1994;13:969-974
-
(1994)
Pediatr Infect Dis J
, vol.13
, pp. 969-974
-
-
Chang, D.1
Liem, L.2
Malogolowkin, M.3
-
13
-
-
0031836683
-
Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients.
-
Krivoy N, Peleg S, Postovsky S, et al. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients. Pediatr Hematol Oncol. 1998;15:333-338
-
(1998)
Pediatr Hematol Oncol
, vol.15
, pp. 333-338
-
-
Krivoy, N.1
Peleg, S.2
Postovsky, S.3
-
14
-
-
0033958126
-
A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.
-
Lamarre P, Lebel D, Ducharme MP. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. Antimicrob Agents Chemother. 2000;44:278-282
-
(2000)
Antimicrob Agents Chemother
, vol.44
, pp. 278-282
-
-
Lamarre, P.1
Lebel, D.2
Ducharme, M.P.3
-
15
-
-
0033806739
-
Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients.
-
Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit. 2000;22:522-531
-
(2000)
Ther Drug Monit
, vol.22
, pp. 522-531
-
-
Wrishko, R.E.1
Levine, M.2
Khoo, D.3
-
16
-
-
81155127325
-
Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children.
-
Giachetto GA, Telechea HM, Speranza N, et al. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children. Pediatr Crit Care Med. 2011;12:e250-e254
-
(2011)
Pediatr Crit Care Med
, vol.12
-
-
Giachetto, G.A.1
Telechea, H.M.2
Speranza, N.3
-
17
-
-
0031756964
-
Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.
-
Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese pediatric patients. Ther Drug Monit. 1998;20:612-618
-
(1998)
Ther Drug Monit
, vol.20
, pp. 612-618
-
-
Yasuhara, M.1
Iga, T.2
Zenda, H.3
-
18
-
-
68949123219
-
An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients
-
Marlowe KF, Chicella MF, Claridge TE, et al. An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients. J Pediatr Pharmacol Ther. 2003;8:132-136
-
(2003)
J Pediatr Pharmacol Ther
, vol.8
, pp. 132-136
-
-
Marlowe, K.F.1
Chicella, M.F.2
Claridge, T.E.3
-
21
-
-
79951804452
-
Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients
-
Kim DI, Im MS, Choi JH, et al. Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients. Korean J Pediatr. 2010;53:1000-1005
-
(2010)
Korean J Pediatr
, vol.53
, pp. 1000-1005
-
-
Kim, D.I.1
Im, M.S.2
Choi, J.H.3
-
22
-
-
79951579705
-
Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.
-
McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158:422-426
-
(2011)
J Pediatr
, vol.158
, pp. 422-426
-
-
McKamy, S.1
Hernandez, E.2
Jahng, M.3
-
23
-
-
84860236045
-
Defining risk factors for red man syndrome in children and adults.
-
Myers AL, Gaedigk A, Dai H, et al. Defining risk factors for red man syndrome in children and adults. Pediatr Infect Dis J. 2012;31:464-468
-
(2012)
Pediatr Infect Dis J
, vol.31
, pp. 464-468
-
-
Myers, A.L.1
Gaedigk, A.2
Dai, H.3
|